News >

SOLO-1 Data Encourage Molecular Testing Immediately at Ovarian Cancer Diagnosis

Ellie Leick
Published: Wednesday, Jul 17, 2019

Thomas Herzog, MD

Thomas Herzog, MD

A key message from the phase III SOLO-1 trial is that patients with ovarian cancer should be tested for BRCA mutations quickly after diagnosis to inform physicians what treatment will be most effective, explained Thomas Herzog, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Community Practice Connections™: Evolutions in the Treatment and Management of Advanced Cervical Cancer: Leveraging the Immunosuppressive Microenvironment, Addressing Ongoing Clinical NeedsJun 30, 20201.5
Publication Bottom Border
Border Publication